136 related articles for article (PubMed ID: 38853537)
1. Diabetic Ketoacidosis as an Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Real World Insights.
Baek HS; Jeong C; Yang Y; Lee J; Lee J; Lee SH; Cho JH; Sohn TS; Son HS; Yoon KH; Lee EY
Diabetes Metab J; 2024 Jun; ():. PubMed ID: 38853537
[TBL] [Abstract][Full Text] [Related]
2. "Normal but Catastrophic" Euglycemic Diabetic Ketoacidosis Precipitated by Sodium-Glucose Cotransporter-2 Inhibitor Use: A Case Report.
Sarno MJF; Hernandez DPF; Matulac MO
Cureus; 2023 Nov; 15(11):e49236. PubMed ID: 38143642
[TBL] [Abstract][Full Text] [Related]
3. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.
Diaz-Ramos A; Eilbert W; Marquez D
Int J Emerg Med; 2019 Sep; 12(1):27. PubMed ID: 31488052
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis in COVID-19-infected patients: A systematic review of case reports.
Khedr A; Hennawi HA; Khan MK; Eissa A; Mir M; Rauf I; Nitesh J; Surani S; Khan SA
World J Clin Cases; 2023 Aug; 11(24):5700-5709. PubMed ID: 37727728
[TBL] [Abstract][Full Text] [Related]
5. Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature.
Mistry S; Eschler DC
AACE Clin Case Rep; 2021; 7(1):17-19. PubMed ID: 33851013
[TBL] [Abstract][Full Text] [Related]
6. A Case of Prolonged Recovery for Post-percutaneous Coronary Intervention (PCI) Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis in a 28-Year-Old.
Petersen C; Gyabaah F; Sotelo J; Yohanna S; Deoker A
Cureus; 2023 Sep; 15(9):e45180. PubMed ID: 37842482
[TBL] [Abstract][Full Text] [Related]
7. Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy.
Dull RB; Spangler ML; Knezevich EL; Lau BM
J Pharm Pract; 2019 Apr; 32(2):240-243. PubMed ID: 29241389
[TBL] [Abstract][Full Text] [Related]
8. On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes.
Horii T; Oikawa Y; Atsuda K; Shimada A
J Diabetes Investig; 2021 Sep; 12(9):1586-1593. PubMed ID: 33448127
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
Goldenberg RM; Berard LD; Cheng AYY; Gilbert JD; Verma S; Woo VC; Yale JF
Clin Ther; 2016 Dec; 38(12):2654-2664.e1. PubMed ID: 28003053
[TBL] [Abstract][Full Text] [Related]
10. A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis.
Patel K; Nair A
Cureus; 2022 Sep; 14(9):e29652. PubMed ID: 36320965
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Burke KR; Schumacher CA; Harpe SE
Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
[TBL] [Abstract][Full Text] [Related]
12. Euglycemic Diabetic Ketoacidosis: Experience with 44 Patients and Comparison to Hyperglycemic Diabetic Ketoacidosis.
Sell J; Haas NL; Korley FK; Cranford JA; Bassin BS
West J Emerg Med; 2023 Nov; 24(6):1049-1055. PubMed ID: 38165186
[TBL] [Abstract][Full Text] [Related]
13. Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients With Type 2 Diabetes Taking SGLT2 Inhibitors.
Vitale RJ; Valtis YK; McDonnell ME; Palermo NE; Fisher NDL
AACE Clin Case Rep; 2021; 7(1):10-13. PubMed ID: 33521255
[TBL] [Abstract][Full Text] [Related]
14. Fall, Fracture, and Two Episodes of Euglycemic Diabetic Ketoacidosis.
Wasey W; Hutchings S; Dufner A; Okon D; Saleh S
Cureus; 2022 Jun; 14(6):e25788. PubMed ID: 35812537
[TBL] [Abstract][Full Text] [Related]
15. SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment.
He Z; Lam K; Zhao W; Yang S; Li Y; Mo J; Gao S; Liang D; Qiu K; Huang M; Wu J
Acta Diabetol; 2023 Mar; 60(3):401-411. PubMed ID: 36576563
[TBL] [Abstract][Full Text] [Related]
16. Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis.
Dutta S; Kumar T; Singh S; Ambwani S; Charan J; Varthya SB
J Family Med Prim Care; 2022 Mar; 11(3):927-940. PubMed ID: 35495849
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose cotransporter-2 (SGLT2) inhibitor-induced euglycemic diabetic ketoacidosis complicating the perioperative management of a patient with type 2 diabetes mellitus (T2DM) and Fournier's gangrene: A case report.
Lindsay PJ; Gibson LE; Bittner EA; Berg S; Chang MG
Int J Surg Case Rep; 2020; 77():463-466. PubMed ID: 33395826
[TBL] [Abstract][Full Text] [Related]
18. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
Musso G; Sircana A; Saba F; Cassader M; Gambino R
PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
[TBL] [Abstract][Full Text] [Related]
19. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Colacci M; Fralick J; Odutayo A; Fralick M
Can J Diabetes; 2022 Feb; 46(1):10-15.e2. PubMed ID: 34116926
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus.
Chauhan S; Manov A; Dhillon GS; Shah P
Cureus; 2023 Jan; 15(1):e33892. PubMed ID: 36819400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]